BioSpace News Archive

Mainz Biomed N.V. is proud to announce the appointment of Tarrin Khairi-Taraki as Vice President of Commercial Operations, EMEA.

Agile Therapeutics, Inc., a women’s healthcare company, announced it will report third quarter 2023 financial results before the market open on Thursday, November 9, 2023.

QIAGEN and Myriad Genetics announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer.

Amarin Corporation plc announced new supported and/or funded research from the landmark REDUCE-IT cardiovascular outcomes trial on the effects of VASCEPA®/VAZKEPA® in a specific patient subgroups at increased risk of a cardiovascular event has been accepted for presentation at the American Heart Association Scientific Sessions 2023, taking place November 11 – 13, 2023 in Philadelphia, PA.

Bionano Genomics, Inc. today announced its participation in the American Society of Human Genetics (ASHG) Annual Meeting 2023 with a broad range of content covering the utility of optical genome mapping (OGM) for cell bioprocessing quality control and constitutional genetic disorder research.

Triumvira Immunologics announced that the first patient has been dosed in Phase II of its Phase I/II study TACTIC-2 investigating the safety and efficacy of autologous TAC-T cell lead asset, TAC01-HER2, in targeting HER2 in relapsed or refractory gastric and gastroesophageal junction tumors.

enVVeno Medical Corporation today reported financial results for the third quarter ended September 30, 2023.

Personalis, Inc., a leader in advanced genomics for precision oncology, announced the launch of the Early Access Program for NeXT Personal Dx, a tumor-informed, whole genome-based liquid biopsy laboratory developed test for detection of molecular residual disease and recurrence in cancer.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its third quarter 2023 financial results and provide an operational update for the Company on Tuesday, November 7, 2023, before the market opens.

Lipocine Inc. announced the completion of a meeting with the FDA and guidance for the appropriate acceptance criteria for the upcoming LPCN 1154 pivotal study.